JOHNSON & JOHNSON
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No SEC Form 4 filings for $JNJ in the last 30 days.
See all $JNJ insider activity →DA Davidson raised its price target for Johnson & Johnson to $270 from $250 while maintaining a buy rating. The company's stock is currently trading at $258.70, up 1.89% on the day and 0.80% over a week.
Johnson & Johnson (JNJ) reported Q3 adjusted EPS of $2.59, beating estimates. The company raised operational sales-growth guidance to 6.7%–7.1% and maintained $21B in free cash flow. Bulls highlight pipeline momentum and technical support, while bears point to margin compression and MedTech weakness. The stock trades at $259.80, with analysts' target upside at 9.8%.
Bernstein raised its price target for Johnson & Johnson (JNJ) to $270 from $261, citing solid Q3 results with 6.1% organic sales growth and EPS beating expectations. The stock is up 24.7% YTD but trades above its Fair Value of $243. Management raised fiscal 2026 guidance but expects flat 2027 EPS growth due to various factors. RBC lowered its target to $280 from $290, maintaining an Outperform rating.
Over the past 7 days, AlphAI's AI scored 152 news stories mentioning JNJ (JOHNSON & JOHNSON). Coverage has skewed bullish: 57 bullish, 48 neutral, and 47 bearish.
Recent JNJ coverage spans financial news, earnings and technology.
Target raise suggests upside potential and may prompt buying interest.
Guidance lift supports upside, but margin compression and MedTech weakness create downside risk.
Target raise suggests modest upside potential.
Potential modest upside if OTTAVA gains market traction; limited immediate impact.
Neutral rating with a lower target may limit upside.
AlphAI scores every news story that mentions JNJ with an AI model for sentiment and relevance, and aggregates insider trades from JOHNSON & JOHNSON's SEC EDGAR Form 4 filings. Figures refresh continuously.
DA Davidson raised its price target for Johnson & Johnson to $270 from $250 while maintaining a buy rating. The company's stock is currently trading at $258.70, up 1.89% on the day and 0.80% over a week.
1 min readJohnson & Johnson (JNJ) reported Q3 adjusted EPS of $2.59, beating estimates. The company raised operational sales-growth guidance to 6.7%–7.1% and maintained $21B in free cash flow. Bulls highlight pipeline momentum and technical support, while bears point to margin compression and MedTech weakness. The stock trades at $259.80, with analysts' target upside at 9.8%.
2 min readBernstein raised its price target for Johnson & Johnson (JNJ) to $270 from $261, citing solid Q3 results with 6.1% organic sales growth and EPS beating expectations. The stock is up 24.7% YTD but trades above its Fair Value of $243. Management raised fiscal 2026 guidance but expects flat 2027 EPS growth due to various factors. RBC lowered its target to $280 from $290, maintaining an Outperform rating.
2 min readJohnson & Johnson (JNJ) trades at a premium, with investors expecting growth. The company raised 2026 guidance and introduced OTTAVA, a new MedTech robotic surgery system. MedTech accounts for 35.9% of revenue. JNJ's stock has outperformed the S&P 500, with a price-to-sales ratio of 6.2. OTTAVA's impact on MedTech's growth remains uncertain. Next earnings report is expected January 26, 2027.
2 min readAnalysts from Morgan Stanley, UBS, and Bernstein updated ratings and price targets for UnitedHealth (UNH), United Therapeutics (UTHR), and Johnson & Johnson (JNJ). UNH received a Buy rating with a $529 target, UTHR a Buy with a $725 target, and JNJ a Hold with a $270 target. Consensus targets suggest upside for all three stocks.
2 min readJohnson & Johnson CFO Joseph Wolk stated the company will use internal investments to drive medtech growth, aiming for double-digit growth by 2030. Q3 medtech sales rose 2.5%, below expectations, but innovative medicine sales offset this. J&J reported $25B in net sales, up 6%, but net earnings dropped 96% YoY due to M&A and litigation costs. The company expects $101B-$101.4B in 2026 sales.
2 min readJohnson & Johnson (J&J) announced a $5.5B talc settlement on July 27, 2026, covering 76,000 ovarian cancer claims. The company expects to pay $3B in 2027, with the total potentially reaching $7B. J&J is also separating its orthopaedics business, DePuy Synthes, with a 2025 sales of $9.3B. Additionally, Kenvue, J&J's consumer health spinoff, was acquired by Kimberly-Clark for $48.7B in 2025. J&J's 2025 sales outlook was $93.5B to $93.9B.
2 min readJohnson & Johnson reported medical device sales of $8.6B, missing estimates of $8.71B, citing geopolitical issues. Shares fell 6%. CFO Joe Wolk attributed weakness to Middle East conflict, European austerity, and China pricing. The company raised its full-year sales forecast to $101.2B and adjusted earnings to $11.10 per share. Pharmaceutical sales rose 7.7% to $16.76B, with Tremfya sales up 68% to $2.4B.
2 min readRBC Capital maintained an 'Outperform' rating for Johnson & Johnson (JNJ) but lowered its price target from $290 to $280. GuruFocus values JNJ at $194.40, suggesting a 28.2% overvaluation. Insiders have sold $67.8M in shares over the past three months, while analysts cite market conditions and competitive pressures for the cautious outlook.
2 min readTelecom stocks VZ, T, TMUS, CHTR fell post-SpaceX acquisition, with VZ gaining 1.75% to $43.53. AMAT dropped 6.69% to $464, citing AI-driven demand. JNJ fell 5.73% to $248.61 after earnings, with drug business up 7.7% and MedTech up 2.5%.
2 min read
